Literature DB >> 17914107

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

Dimitrios Spentzos1, Stephen A Cannistra, Franck Grall, Douglas A Levine, Kamana Pillay, Towia A Libermann, Christos S Mantzoros.   

Abstract

The IGF axis has documented growth-promoting effects in various malignancies, but its role in epithelial ovarian cancer (EOC) has not been adequately examined. We studied the expression of the IGF axis genes in relation to outcome in EOC. Microarray expression profiles from 64 patients with advanced-stage EOC were used. Two multi-gene subsets were chosen, one upstream of the IGF receptor ('IGF family') and the other downstream of the IGF receptor ('IGF signaling pathway'), and analyzed in relation to survival. In addition, expression patterns of the two gene subsets were analyzed in relation to favorable and unfavorable prognosis categories identified in a previous study by whole-genome expression profiling. In a gene-by-gene analysis, IGF binding protein 4 and IGF-II receptor gene expression was inversely associated with survival. Using hierarchical clustering, the two multi-gene subsets separated the patient cohort into two groups with different median survival (IGF family: 33 vs 63 months, P=0.02 and IGF signaling pathway: 41 vs 63 months, P=0.05). Furthermore, the two multi-gene subsets were differentially expressed between the previously defined favorable and unfavorable prognosis tumors (Kolmogorov-Smirnov permutation: P=0.0005 and 0.003 for the IGF family and signaling pathway respectively), and individual genes (including IGF-I, IGF-I receptor, and several genes downstream of the receptor) were overexpressed in unfavorable prognosis tumors (permutation P<0.05). The expression patterns of several genes in the IGF axis are associated with survival in EOC, and expression changes of these genes may be underlying previously proposed microarray-derived clinical prognostic models. Future studies are needed to more precisely determine the diagnostic and potential therapeutic significance of these findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914107     DOI: 10.1677/ERC-06-0073

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  23 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

Review 3.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 4.  Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.

Authors:  Eric R Craig; Angelina I Londoño; Lyse A Norian; Rebecca C Arend
Journal:  Gynecol Oncol       Date:  2016-10-15       Impact factor: 5.482

5.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Authors:  Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Gynecol Oncol       Date:  2011-07-02       Impact factor: 5.482

6.  Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer.

Authors:  Yonglian Zhu; José B Fariña; Syrus Meshack; Ana Santoveña; Shilpa Patel; Alexis Oliva; Matias Llabrés; Michael E Hodsdon; Carmen J Booth; Priscilla S Dannies
Journal:  Endocrine       Date:  2010-04-20       Impact factor: 3.633

Review 7.  The role of adiponectin in cancer: a review of current evidence.

Authors:  Maria Dalamaga; Kalliope N Diakopoulos; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2012-04-30       Impact factor: 19.871

8.  Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Authors:  M Teresa Agulló-Ortuño; C Vanesa Díaz-García; Alba Agudo-López; Carlos Pérez; Ana Cortijo; Luis Paz-Ares; Fernando López-Ríos; Francisco Pozo; Javier de Castro; Hernán Cortés-Funes; José A López Martín
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-01       Impact factor: 4.553

9.  Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Authors:  Valentine M Macaulay; Mark R Middleton; S Gail Eckhardt; Charles M Rudin; Rosalyn A Juergens; Richard Gedrich; Sven Gogov; Sean McCarthy; Srinivasu Poondru; Andrew W Stephens; Shirish M Gadgeel
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

10.  Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Authors:  Marie-Claude Beauchamp; Amber Yasmeen; Ariane Knafo; Walter H Gotlieb
Journal:  J Oncol       Date:  2010-01-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.